MDX Medical Inc.

MDX Medical Inc.

May 23, 2006 13:08 ET

MDX Completes Patient Enrollment for CIHR Study of NIRS Technology

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 23, 2006) - MDX Medical Inc. (TSX VENTURE:MDX) announced today it has completed patient enrollment for the clinical study of its near infra-red spectrophotometry (NIRS) urodynamics technology led by Drs. Lynn Stothers and Andrew Macnab at the UBC Bladder Care Center. The study, supported by MDX and a grant from The Canadian Institutes of Health Research (CIHR), consists of a series of human clinical experiments to support the commercialization of the new technology. The completion of the study is in line with MDX's disclosed commercialization plan. (See news release Feb. 22, 2006).

This study evaluated the performance of NIRS compared to traditional catheter based urodynamics systems in 43 subjects suffering from urinary incontinence. It also studied natural filling and bladder function in 31 healthy normal subjects. Drs. Stothers and Macnab will present a subset of this clinical data at the Annual General Meeting of the American Urology Association (AUA) May 24, 2006 in Atlanta. Attendance at the AUA is typically in excess of 30,000 delegates. It is expected that the complete analysis of the results will be available within 60 days.

MDX's NIRS technology is a breakthrough in bladder care providing non-invasive monitoring and diagnosis of bladder dysfunction including urinary incontinence. NIRS will eliminate the need and discomfort for patient catheterization while reducing procedure time and costs.

Barry Allen, President and Chief Executive Officer, said, "We are confident this study will confirm the performance of the NIRS technology in its intended population and environment. The results will support MDX's ongoing efforts towards commercial launch of NIRS in late 2007."

About MDX Medical:

MDX Medical Inc. (TSX VENTURE:MDX) is an early stage medical device Company focused on the development and commercialization of breakthrough diagnostic technology for bladder conditions specifically Urinary Incontinence. MDX is currently developing a family of non-invasive diagnostic and monitoring technologies for these conditions which affects over 3.3M Canadians and 25M Americans. For more information about MDX, please visit our website at:

On behalf of the Board,

Barry Allen, President & CEO

MDX Medical Inc.

Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein. Although the Company believes that the expectations reflected in such forward looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information